• China Traditional Chinese Medicine Holdings said China’s NMPA cleared its Class 1.1 TCM innovative drug Xingpi Jieyu Tablets for market launch.
• Marketing authorization holder: Sinopharm Group Tongjitang (Guizhou) Pharmaceutical, a group subsidiary.
• Drug targets mild-to-moderate depression; Phase III trial completed in 2024 showed safety, efficacy, outperformance versus placebo.
• Approval expands the group’s proprietary Chinese medicine portfolio; earnings impact depends on production, sales, reimbursement, tenders, competition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12321999), on September 04, 2026, and is solely responsible for the information contained therein.